Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Phase 4

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07297316Phase 4Completed

Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease

Role: collaborator

NCT06177678Phase 2Unknown

A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Role: lead

NCT05017844Phase 2Completed

[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome

Role: lead

NCT05017870Phase 1Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Role: lead

NCT03509831Phase 1Unknown

[KJ-INT-002] BE Study

Role: lead

NCT02967614Phase 1Completed

KJ-TFC-004 Drug-drug Interaction Study

Role: lead

All 6 trials loaded